Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy

Oncology

Volumn 72, Issue 5-6, 2008, Pages 388-396

  Tzaida, Olympia ^a   Gogas, Helen ^b,m   Dafni, Urania ^e   Kyroudi, Aspasia ^d   Papaspyrou, Irene ^h   Kyriakou, Vasiliki ^b   Malamou Mitsi, Vasiliki ⁱ   Alamani, Maria ^f   Skopa, Chrisoula ^j   Kostopoulos, Ioannis ^l   Kastritis, Efstathios ^h   Pectasides, Dimitrios ^c   Briasoulis, Evangelos ⁱ   Kalofonos, Haralabos P ^j   Aravantinos, Gerasimos ^g   Fountzilas, George ^k,l   Arapantoni Dadioti, Petroula ^a  

^a METAXA CANCER HOSPITAL   (Greece)

^b LAIKO GENERAL HOSPITAL   (Greece)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e UNIVERSITY OF ATHENS   (Greece)

^f HENRY DUNANT HOSPITAL   (Greece)

^g AGII ANARGIRI CANCER HOSPITAL   (Greece)

^h ALEXANDRA HOSPITAL   (Greece)

ⁱ UNIVERSITY OF IOANNINA   (Greece)

^j UNIVERSITY OF PATRAS   (Greece)

^k PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

^l ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^m Hellenic Cooperative Oncology Group   (Greece)

more..

Author keywords

Breast cancer; EGFR; HER 1; HER 2; p53; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RISK; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; GENES, ERBB-1; HUMANS; IMMUNOHISTOCHEMISTRY; METHOTREXATE; MIDDLE AGED; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 39049108100     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000113148     Document Type: Article

References (46)

1. Early Breast Cancer Trialists Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930-942.
2. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
3. Gusterson BA: The changing role of the pathologist in the prediction of tumor behaviour and response to treatment; in Dickson RB, Lippman ME (eds): Drug and Hormonal Resistance in Breast Cancer. New York, Horwood, 1995, pp 39-53.
4. Gullick WJ, Srinivassan R: The type I growth factor receptor family: new ligands and receptors and their role in breast cancer. Cancer Res Treat 1998;52:43-53.
5. Hackel PO, Zwick E, Prenzel N, et al: Epidermal growth factor receptors;critical mediators of receptor pathways. Curr Opin Cell Biol 1999;11:184-189.
6. Kurie JM, Shin HJ, Lee JS, et al: Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996;2:1787-1793.
7. Prenzel N, Fischer OM, Streit S, et al: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11-31.
8. Yarden Y: The HER-1/ E GFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37:53-58.
9. Yarden Y, Sliwkowski MX: Untangling the Erb signaling network. Nat Rev Mol Cell Biol 2001;2:127-137.
10. Velu TJ, Berguinot L, Vass WC, et al: Epidermal growth factor-dependent transformation by a human EGF receptor proto-oncogene. Science 1987;238:1408-1410.
11. Arteaga CL: Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;5:3-9.
12. Pavelic K, Banjac Z, Pavelic J, et al: Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993;13:1133-1138.
13. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ: Tyrosine kinase signaling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000;2:203-210.
14. Lichtner RB, Kaufman AM, Kittman A, et al: Ligand mediated activation of ectopic EGF receptor promotes matrix protein adhesion and lung colonization of rat mammary adenocarcinoma cells. Oncogene 1993;10:1823-1832.
15. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987;i1:1398-1402.
16. Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Fandom JR, Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet 1989;i:182-185.
17. Yarden RI, Lauber AH, El Ashry D, et al: Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. Endocrinology 1996;137:2739-2747.
18. Bunone G, Briand PA, Miksicek RJ, et al: Activation of the unliganded estrogen by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-2183.
19. Zwick E, Bange J, Ulrich A: Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 2002;8:17-23.
20. Bundred NJ, Chan K, Anderson NG: Studies of epidermal growth factor receptor inhibition in breast cancer. Endocr Relat Cancer 2001;8:183-189.
21. Kurokawa H, Arteaga CL: Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 2001;7(suppl 12):4436s-4442s.
22. Laskin JJ, Sandler AB: Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004;30:1-17.
23. Fountzilas G, Skarlos D, Dafni U, et al: Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high risk operable breast cancer. A randomised phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2005;16:1762-1711.
24. Bloom HJ, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359-377.
25. Kostopoulos I, Arapantoni-Dadioti P, Gogas H, et al: Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res Treat 2006;96:251-261.
26. Malamou-Mitsi B, Gogas H, Dafni U, et al: Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol 2006;17:1504-1511.
27. McShane LM, Altman DG, Sauerbrei W, et al: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 2006;100:229-235.
28. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7:31-39.
29. Newby JC, A'Hern DP, Leek RD, Smith IE, Harris AL, Dowsett M: Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. Br J Cancer 1995;71:1237-1242.
30. Klijn JG, Berns PM, Schmitz PI, Foekens JA: The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992;13:3-17.
31. Klijn JG, Look MP, Portengen H, et al: The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 1994;29:73-83.
32. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL: The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3,009 patients. Breast Cancer Res Treat 1994;29:41-49.
33. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-297.
34. Toi M, Nakamura T, Mukaida H, et al: Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 1990;65:1980-1984.
35. Ferrero JM, Ramaioli R, Largillier R, Formento JL, Francoual M, et al: Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight year median follow-up. Ann Oncol 2001;12:841-846.
36. Charpin C, Devictor B, Bionner P, et al: Epidermal growth factor receptor in breast cancer: correlation of quantitative immunocytochemical assays to prognostic factors. Breast Cancer Res Treat 1993;25: 203-210.
37. Spyratos F, Martin PM, Hacene K, et al: Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay - a retrospective study. Breast Cancer Res Treat 1994;29:85-95.
38. Oehler MK, Rehn M, Kristen P, et al: Correlation of the EGF receptor with cell kinetic and classical prognostic factors in breast cancer. Anticancer Res 1997;17:3137-3140.
39. Megha T, Ferrari F, Benvenuto A, et al: p53 mutation in breast cancer. Correlation with cell kinetics. J Clin Pathol 2002;55:461-466.
40. Osaki A, Toi M, Yamada H, et al: Prognostic significance of co-expression of c-erb2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am J Surg 1992;164:323-326.
41. Harlozinska A, Bar JK, Wenderski R, Bebenek M: Relationship between c-erb2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes. In vivo 1996;10:217-222.
42. Harris AL, Nicholson S, Sainsbury JRC, et al: Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interaction with neu. J Steroid Biochem 1989;34:123-131.
43. Di Giovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D II, Thor AD: Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005;23:1152-1160.
44. Nicholson RI, McClelland RA, Finlay P, et al: Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993;29A:1018-1023.
45. Normanno N, Campiglio M, De LA, Somenzi G, et al: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13:65-72.
46. Tsutsui S, Ohno S, Murakami S, et al: Prognostic value of epidermal growth factor receptor (HER-1/ E GFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002;71:67-75.